MedTrace Logo

A Pharmacodynamic Study of TS-172 in Healthy Adult Male Subjects

NCT07084961 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2025-10-03

No results posted yet for this study

Summary

An open-label, single-center, crossover study to evaluate the impact of administration timing of TS-172 on the pharmacodynamics in healthy adult male subjects.

Conditions

  • Healthy Adult Male Subjects

Interventions

DRUG

TS-172

Oral administration of TS-172 20 mg immediately before meal

DRUG

TS-172

Oral administration of TS-172 20 mg immediately after meal

Sponsors & Collaborators

  • Taisho Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Taisho Director Taisho Director · Taisho Pharmaceutical Co., Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
39 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-08-05
Primary Completion
2025-09-11
Completion
2025-09-16

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07084961 on ClinicalTrials.gov